Ads
related to: anti-cancer treatment
Search results
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology via Yahoo Finance· 7 days agoAdditionally, among the 26 patients enrolled by the cutoff date, the regimen demonstrated a...
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 1 day agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a...
WPRI Providence· 7 days agoTyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been ...
Plant-Based Diets Lower The Risk Of Prostate Cancer Progressing By 47%
Forbes· 2 days agoA recent JAMA Network Open study of men who were diagnosed with prostate cancer found that people...
King to take part in Trooping the Colour ceremony
Press Association News via AOL· 12 hours agoGuardsmen on parade during Trooping the Colour. Aaron Chown/PA Republic, the anti-monarchy group, has said it will stage the latest in a string of...
Cell therapy reckoning: How a 'remarkable resolution of lupus' carried CAR-T from cancer to...
FierceBiotech· 12 hours agoGabrielle Masson, Helen Floersh, James Waldron and Max Bayer contributed reporting to this series....
FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity - Nature...
Nature· 18 hours agoThe immunosuppressive tumour microenvironment in Nasopharyngeal carcinoma (NPC) is a cause of low efficacy of immunotherapies in these tumours. In this study, the authors delineate a FLI1-mediated ...
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Digital Journal· 3 days ago(NASDAQ: BGNE) (“BeiGene”) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s next generation immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab ...
Harnessing the power of viruses to kill cancers
Medical Xpress· 6 days agoPathogens—those bugs that routinely infect and sicken us, like the common cold or influenza—are being studied in labs around the world to see if they can be used safely and effectively to attack ...
Press Release: Sarclisa accepted for FDA priority review for thetreatment of transplant-ineligible...
Benzinga· 4 days agoIf approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be ...